Circadin

RSS

melatonin

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 17/05/2023

Authorisation details

Product details
Name
Circadin
Agency product number
EMEA/H/C/000695
Active substance
melatonin
International non-proprietary name (INN) or common name
melatonin
Therapeutic area (MeSH)
Sleep Initiation and Maintenance Disorders
Anatomical therapeutic chemical (ATC) code
N05CH01
Publication details
Marketing-authorisation holder
RAD Neurim Pharmaceuticals EEC SARL
Revision
34
Date of issue of marketing authorisation valid throughout the European Union
29/06/2007
Contact address

4 rue de Marivaux
75002 Paris
France

Product information

16/05/2023 Circadin - EMEA/H/C/000695 - IAIN/0070

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Psycholeptics

Therapeutic indication

Circadin is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.

Assessment history

Related content

How useful was this page?

Add your rating
Average
2 ratings
2 ratings
2 ratings